Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionGreenleaf Trust
Latest Disclosed Ownership4,753 shares
Latest Disclosed Value $ 2,122,405
Greenleaf Trust reports 0.23% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 27, 2026 - Greenleaf Trust filed a 13F-HR form disclosing ownership of 4,753 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $2,122,405 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 21, 2026 disclosing 4,742 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 0.23% during the quarter. The current value of the position is $2,035,900 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-27 2026-03-31 13F Vertex Pharmaceuticals Com 92532F100 4,753 11 0.23 2,122 -1.26 0.0117
2026-01-21 2025-12-31 13F Vertex Pharmaceuticals Com 92532F100 4,742 39 0.83 2,150 16.73 0.0197
2025-10-22 2025-09-30 13F Vertex Pharmaceuticals Com 92532F100 4,703 -334 -6.63 1,842 -17.89 0.0167
2025-07-17 2025-06-30 13F Vertex Pharmaceuticals Com 92532F100 5,037 -729 -12.64 2,242 -19.79 0.0198
2025-04-30 2025-03-31 13F Vertex Pharmaceuticals Com 92532F100 5,766 272 4.95 2,795 26.36 0.0255
2025-01-24 2024-12-31 13F Vertex Pharmaceuticals COM 92532F100 5,494 79 1.46 2,212 -12.15 0.0201
2024-10-22 2024-09-30 13F Vertex Pharmaceuticals COM 92532F100 5,415 19 0.35 2,518 -0.43 0.0224
2024-07-22 2024-06-30 13F Vertex Pharmaceuticals COM 92532F100 5,396 426 8.57 2,529 21.76 0.0240
2024-04-29 2024-03-31 13F Vertex Pharmaceuticals COM 92532F100 4,970 -7 -0.14 2,078 2.57 0.0193
2024-01-31 2023-12-31 13F Vertex Pharmaceuticals COM 92532F100 4,977 67 1.36 2,025 18.63 0.0217
2023-11-09 2023-09-30 13F Vertex Pharmaceuticals COM 92532F100 4,910 166 3.50 1,707 2.28 0.0197
2023-08-09 2023-06-30 13F Vertex Pharmaceuticals COM 92532F100 4,744 -255 -5.10 1,669 5.97 0.0177
2023-05-11 2023-03-31 13F Vertex Pharmaceuticals COM 92532F100 4,999 7 0.14 1,575 157,400.00 0.0178
2023-01-25 2022-12-31 13F Vertex Pharmaceuticals COM 92532F100 4,992 362 7.82 1 -99.93 0.0183
2022-11-10 2022-09-30 13F Vertex Pharmaceuticals COM 92532F100 4,630 -30 -0.64 1,341 2.13 0.0198
2022-08-12 2022-06-30 13F Vertex Pharmaceuticals COM 92532F100 4,660 296 6.78 1,313 15.28 0.0199
2022-04-27 2022-03-31 13F Vertex Pharmaceuticals COM 92532F100 4,364 667 18.04 1,139 40.27 0.0136
2022-02-11 2021-12-31 13F Vertex Pharmaceuticals COM 92532F100 3,697 1,607 76.89 812 114.25 0.0095
2021-11-12 2021-09-30 13F Vertex Pharmaceuticals COM 92532F100 2,090 -1,061 -33.67 379 -40.31 0.0046
2021-08-10 2021-06-30 13F Vertex Pharmaceuticals COM 92532F100 3,151 -316 -9.11 635 -14.77 0.0079
2021-04-30 2021-03-31 13F Vertex Pharmaceuticals COM 92532F100 3,467 355 11.41 745 1.36 0.0098
2021-02-08 2020-12-31 13F Vertex Pharmaceuticals COM 92532F100 3,112 214 7.38 735 -6.84 0.0098
2020-10-30 2020-09-30 13F Vertex Pharmaceuticals COM 92532F100 2,898 -115 -3.82 789 -9.83 0.0122
2020-08-12 2020-06-30 13F Vertex Pharmaceuticals COM 92532F100 3,013 388 14.78 875 40.00 0.0153
2020-04-29 2020-03-31 13F Vertex Pharmaceuticals COM 92532F100 2,625 306 13.20 625 23.03 0.0124
2020-02-11 2019-12-31 13F Vertex Pharmaceuticals COM 92532F100 2,319 0 0.00 508 29.26 0.0080
2019-11-08 2019-09-30 13F Vertex Pharmaceuticals COM 92532F100 2,319 218 10.38 393 2.08 0.0061
2019-07-24 2019-06-30 13F Vertex Pharmaceuticals COM 92532F100 2,101 -42 -1.96 385 -2.28 0.0061
2019-05-08 2019-03-31 13F Vertex Pharmaceuticals COM 92532F100 2,143 335 18.53 394 31.33 0.0065
2019-02-07 2018-12-31 13F Vertex Pharmaceuticals COM 92532F100 1,808 140 8.39 300 -6.54 0.0059
2018-10-29 2018-09-30 13F Vertex Pharmaceuticals COM 92532F100 1,668 216 14.88 321 29.96 0.0058
2018-08-07 2018-06-30 13F Vertex Pharmaceuticals COM 92532F100 1,452 1,452 247 0.0047
2018-04-30 2018-03-31 13F Vertex Pharmaceuticals COM 92532F100 0 -152 -100.00 0 -100.00
2018-02-08 2017-12-31 13F Vertex Pharmaceuticals COM 92532F100 152 -30 -16.48 23 -17.86 0.0005
2017-11-13 2017-09-30 13F Vertex Pharmaceuticals COM 92532F100 182 182 28 0.0006
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.